ArticleChinese journal of integrative medicine2026
Icaritin Disrupts Cholesterol Biosynthesis and Induce Cell Death in Pancreatic Carcinoma: A Transcriptomic and Lipidomic Analysis.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the effects of icaritin on pancreatic cancer cell proliferation and the mechanisms underlying cell death.
methodsTranscriptomic and lipidomic analyses were performed on the pancreatic cancer cell lines pancreatic carcinoma 1 (PANC-1) and ascites of the pancreas carcinoma 1 (ASPC1) treated with icaritin (0, 25 µ, mol/L) to profile global gene expression and lipid metabolism alterations. Key cholesterol biosynthesis genes were validated via quantitative reverse transcription polymerase chain reaction and Western blot. Additionally, cell viability was assessed using luminescent assays, while cytoplasmic vacuolization (paraptosis marker) was observed microscopically. Total cholesterol levels were quantified enzymatically, and lipid species (e.g., phosphatidylcholine, triglycerides) were analyzed by principal component analysis and pathway enrichment.
resultsIcaritin significantly altered lipid metabolism in pancreatic cancer cells by elevating membrane lipids such as phosphatidylcholine, ceramide, sphingomyelin, and phosphatidylethanolamines (P<0.05). Concurrently, it reduced the levels of energy-supplying lipids including triglycerides, diglycerides, and acylcarnitines (P<0.05). There was also a notable decrease in cholesteryl ester 24:1 levels, which is consistent with the suppression of cholesterol biosynthesis (P<0.05 or P<0.01). Icaritin inhibited the proliferation of PANC-1 and ASPC1 cells by downregulating key cholesterol biosynthesis genes, such as 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene epoxidase genes (P<0.01).
conclusionsIcaritin disrupts lipid metabolism and inhibits cholesterol biosynthesis in pancreatic cancer cells, leading to non-apoptotic cell death. This novel mechanism of action provides new therapeutic possibilities for the treatment of pancreatic cancer and highlights its potential as a targeted anticancer agent.
Indexed as
Identifiers
41920258What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.